Walia Harpreet S, Shah Gaurav K, Blinder Kevin J
The Retina Institute, St. Louis, Mo.
The Retina Institute, St. Louis, Mo.
Can J Ophthalmol. 2016 Apr;51(2):91-6. doi: 10.1016/j.jcjo.2015.11.007.
To assess the efficacy and safety of intravitreal aflibercept injection in the treatment of CNV secondary to presumed ocular histoplasmosis syndrome (POHS).
To assess safety of intravitreal aflibercept for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome.
Masked, open-label, prospective study. Five subjects will receive 2.0 mg aflibercept injection every 8 weeks with 3 initial monthly doses over a 12 month period.
No adverse systemic or ocular were reported. At month six, the mean visual acuity improved by 7.8 ETDRS letters, mean central subfoveal thickness decreased by 38.8 microns and mean OCT volume decreased by 0.076 mm3 . At month twelve, the mean visual acuity improved by 12.4 ETDRS letters, mean central subfoveal thickness decreased by 34.6 microns and mean OCT volume decreased by 0.576 mm3.
The use of intravitreal 2.0 mg aflibercept injection for the treatment of CNV secondary to presumed ocular histoplasmosis syndrome yielded no systemic or ocular adverse events and produced improvement in visual acuity and reduction of OCT thickness and volume.
评估玻璃体内注射阿柏西普治疗疑似眼组织胞浆菌病综合征（POHS）继发的脉络膜新生血管（CNV）的疗效和安全性。
评估玻璃体内注射阿柏西普治疗疑似眼组织胞浆菌病综合征继发的CNV的安全性。
遮蔽、开放标签的前瞻性研究。五名受试者将在12个月内每8周接受一次2.0毫克阿柏西普注射，初始每月注射3次。
未报告全身性或眼部不良事件。在第6个月时，平均视力提高了7.8个早期糖尿病性视网膜病变研究（ETDRS）字母，平均黄斑中心凹下厚度减少了38.8微米，平均光学相干断层扫描（OCT）体积减少了0.076立方毫米。在第12个月时，平均视力提高了12.4个ETDRS字母，平均黄斑中心凹下厚度减少了34.6微米，平均OCT体积减少了0.576立方毫米。
使用玻璃体内注射2.0毫克阿柏西普治疗疑似眼组织胞浆菌病综合征继发的CNV未产生全身性或眼部不良事件，并改善了视力，降低了OCT厚度和体积。
Zotero 插件